<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33588903</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1750-1172</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Orphanet journal of rare diseases</Title>
          <ISOAbbreviation>Orphanet J Rare Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials.</ArticleTitle>
        <Pagination>
          <StartPage>87</StartPage>
          <MedlinePgn>87</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">87</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13023-021-01694-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Multiple sclerosis (MS) is a chronic illness involving the central nervous system (CNS) that is characterised by inflammation, demyelination, and degenerative changes. Dalfampridine is one of the available treatments for MS symptoms and comorbidities. This meta-analysis aimed to assess the safety and benefits of dalfampridine versus placebo in MS by summarising data deriving from previously published clinical randomised controlled studies (RCTs).</AbstractText>
          <AbstractText Label="RESULTS">A total of 9 RCTs were included in this meta-analysis, involving 1691 participants. There were significant differences between dalfampridine and placebo in terms of decreased 12-item Multiple Sclerosis Walking Scale score (weighted mean difference [WMD] =  - 3.68, 95% confidence interval [CI] [- 5.55, - 1.80], p = 0.0001), improved response to the timed 25-foot walk test (relative risk [RR] = 2.57, 95% CI [1.04, 6.33], p = 0.04), increased 6-min walk test (WMD = 18.40, 95% CI [1.30, 35.51], p = 0.03), increased 9-Hole Peg Test score (WMD = 1.33, 95% CI [0.60, 2.05], p = 0.0004), and increased Symbol Digit Modalities Test score (WMD = 4.47, 95% CI [3.91, 5.02], p &lt; 0.00001). Significant differences in the incidence of side effects were also observed (RR = 1.12, 95% CI [1.04, 1.21], p = 0.002).</AbstractText>
          <AbstractText Label="CONCLUSION">Dalfampridine exerts positive effects on walking ability, finger dexterity, and cognitive function. Treatment should be administered under the guidance of a physician or pharmacist given the higher incidence of adverse events.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Enyao</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ruoming</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chaoyang</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Lingyun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China. zhouying0321@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yimin</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-4186-1005</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University First Hospital, 6 Dahongluochang Street, Xicheng District, Beijing, 100034, China. bdyyyljd@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Orphanet J Rare Dis</MedlineTA>
        <NlmUniqueID>101266602</NlmUniqueID>
        <ISSNLinking>1750-1172</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="Y">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Dalfampridine</Keyword>
        <Keyword MajorTopicYN="Y">Meta-analysis</Keyword>
        <Keyword MajorTopicYN="Y">Multiple sclerosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33588903</ArticleId>
        <ArticleId IdType="pmc">PMC7885571</ArticleId>
        <ArticleId IdType="doi">10.1186/s13023-021-01694-8</ArticleId>
        <ArticleId IdType="pii">10.1186/s13023-021-01694-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Montalban X, Gold R, Thompson AJ, et al.  ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):605. doi: 10.1111/ene.13536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.13536</ArticleId>
            <ArticleId IdType="pubmed">29352526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636. doi: 10.1016/S0140-6736(18)30481-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)30481-1</ArticleId>
            <ArticleId IdType="pubmed">29576504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group et al.  New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136. doi: 10.1177/1352458517694432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517694432</ArticleId>
            <ArticleId IdType="pmc">PMC5476197</ArticleId>
            <ArticleId IdType="pubmed">28273775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamore R, III, Jacob E, Jacob SC, Hilas O. Dalfampridine (Ampyra): an aid to walking in patients with multiple sclerosis. P T Peer Rev J Formul Manag. 2010;35(12):665–669.</Citation>
        </Reference>
        <Reference>
          <Citation>Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40. doi: 10.1111/ene.13819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.13819</ArticleId>
            <ArticleId IdType="pubmed">30300457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtiss FR. Pharmacoeconomic modeling of drug therapies for multiple sclerosis—are we building houses on sand? J Manag Care Pharm. 2007;13(3):287–289. doi: 10.18553/jmcp.2007.13.3.287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18553/jmcp.2007.13.3.287</ArticleId>
            <ArticleId IdType="pubmed">17407397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockl KM, Shin JS, Gong S, Harada AS, Solow BK, Lew HC. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care. 2010;16(2):139–144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20148619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes KC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004;10(4):295–316. doi: 10.1111/j.1527-3458.2004.tb00029.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1527-3458.2004.tb00029.x</ArticleId>
            <ArticleId IdType="pmc">PMC6741729</ArticleId>
            <ArticleId IdType="pubmed">15592580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2018. https://www.accessdata.fda/gov. Cited 26 Sept 2018. Retrieved from: http://fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;applno=022250.</Citation>
        </Reference>
        <Reference>
          <Citation>Shi J, Wu X, Chen Y. Study on dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: a meta-analysis. PLoS ONE. 2019;14(9):e0222288. doi: 10.1371/journal.pone.0222288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0222288</ArticleId>
            <ArticleId IdType="pmc">PMC6742383</ArticleId>
            <ArticleId IdType="pubmed">31513613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S, et al.  Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33(11):1087–1099. doi: 10.1007/s40263-019-00671-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-019-00671-x</ArticleId>
            <ArticleId IdType="pubmed">31612418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–846. doi: 10.1002/ana.20703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20703</ArticleId>
            <ArticleId IdType="pubmed">16283615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi: 10.1002/ana.22366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22366</ArticleId>
            <ArticleId IdType="pmc">PMC3084507</ArticleId>
            <ArticleId IdType="pubmed">21387374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.33.11.1444</ArticleId>
            <ArticleId IdType="pubmed">6685237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, et al.  Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, Phase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33(1):61–79. doi: 10.1007/s40263-018-0586-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-018-0586-5</ArticleId>
            <ArticleId IdType="pmc">PMC6328522</ArticleId>
            <ArticleId IdType="pubmed">30535670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, et al.  Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult Scler. 2016;22(2):212–221. doi: 10.1177/1352458515581436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515581436</ArticleId>
            <ArticleId IdType="pmc">PMC4749757</ArticleId>
            <ArticleId IdType="pubmed">25921050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, et al.  Evaluation of dalfampridine extended release 5 and 10 mg in Multiple Sclerosis: a randomized controlled trial. Int J MS Care. 2015;17(3):138–145. doi: 10.7224/1537-2073.2014-040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7224/1537-2073.2014-040</ArticleId>
            <ArticleId IdType="pmc">PMC4455866</ArticleId>
            <ArticleId IdType="pubmed">26052259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al.  A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494–502. doi: 10.1002/ana.22240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22240</ArticleId>
            <ArticleId IdType="pubmed">20976768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen HB, Nielsen JL, Ravnborg M, Dalgas U, Aagaard P, Stenager E. Effect of slow release-fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Mult Scler Relat Disord. 2016;10:137–144. doi: 10.1016/j.msard.2016.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2016.07.019</ArticleId>
            <ArticleId IdType="pubmed">27919481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacques F, Schembri A, Nativ A, Paquette C, Kalinowski P. Prolonged-release fampridine as adjunct therapy to active motor training in MS Patients: a pilot, double-blind, randomized, placebo-controlled study. Mult Scler J Exp Transl Clin. 2018 doi: 10.1177/2055217318761168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2055217318761168</ArticleId>
            <ArticleId IdType="pmc">PMC5846958</ArticleId>
            <ArticleId IdType="pubmed">29552356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, et al.  Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019;93(8):e733–e746. doi: 10.1212/WNL.0000000000007970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000007970</ArticleId>
            <ArticleId IdType="pubmed">31331968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marion S, Leonid C, Belinda B, Joanne D, Elise H, Leeanne C, et al.  Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2020;40:101971. doi: 10.1016/j.msard.2020.101971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.101971</ArticleId>
            <ArticleId IdType="pubmed">32062444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arreola-Mora C, Silva-Pereyra J, Fernández T, Paredes-Cruz M, Bertado-Cortés B, Grijalva I. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: randomized, double-blind, placebo-controlled clinical trial. Preliminary report [preliminary report] Mult Scler Relat Disord. 2019;28:117–124. doi: 10.1016/j.msard.2018.12.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2018.12.026</ArticleId>
            <ArticleId IdType="pubmed">30593980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509–1517. doi: 10.1212/WNL.0b013e31828cf7f3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31828cf7f3</ArticleId>
            <ArticleId IdType="pubmed">23535489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidovar MF, Limone BL, Coleman CI. Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. Patient Relat Outcome Meas. 2016;7:13–18. doi: 10.2147/PROM.S96956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/PROM.S96956</ArticleId>
            <ArticleId IdType="pmc">PMC4745957</ArticleId>
            <ArticleId IdType="pubmed">26893584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18(7):914–924. doi: 10.1177/1352458512444498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458512444498</ArticleId>
            <ArticleId IdType="pubmed">22740603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myhr KM, Riise T, Vedeler C, Nortvedt MW, Grønning R, Midgard R, et al.  Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001;7(1):59–65. doi: 10.1177/135245850100700110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/135245850100700110</ArticleId>
            <ArticleId IdType="pubmed">11321195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? Q J Med. 2004;97(10):671–676. doi: 10.1093/qjmed/hch105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/qjmed/hch105</ArticleId>
            <ArticleId IdType="pubmed">15367738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edgley K, Sullivan MJ, Dehoux E. A survey of multiple sclerosis: II. Determinants of employment status. Can J Rehabil. 1991;4(3):127–132.</Citation>
        </Reference>
        <Reference>
          <Citation>Calkins DR, Rubenstein LV, Cleary PD, Davies AR, Jette AM, Fink A, et al.  Failure of physicians to recognize functional disability in ambulatory patients. Ann Intern Med. 1991;114(6):451–454. doi: 10.7326/0003-4819-114-6-451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-114-6-451</ArticleId>
            <ArticleId IdType="pubmed">1825267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman JA. Improving mobility and functional independence in persons with multiple sclerosis. J Neurol. 2001;248(4):255–259. doi: 10.1007/s004150170198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004150170198</ArticleId>
            <ArticleId IdType="pubmed">11374088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald I, Compston A.  The symptoms and signs of multiple sclerosis. London: Churchill Livingstone; 2006. </Citation>
        </Reference>
        <Reference>
          <Citation>Kamm CP, Heldner MR, Vanbellingen T, Mattle HP, Müri R, Bohlhalter S. Limb apraxia in multiple sclerosis: prevalence and impact on manual dexterity and activities of daily living. Arch Phys Med Rehabil. 2012;93(6):1081–1085. doi: 10.1016/j.apmr.2012.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apmr.2012.01.008</ArticleId>
            <ArticleId IdType="pubmed">22464095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch MW, Murray TJ, Fisk J, Greenfield J, Bhan V, Jacobs P, et al.  Hand dexterity and direct disease related cost in multiple sclerosis. J Neurol Sci. 2014;341(1–2):51–54. doi: 10.1016/j.jns.2014.03.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2014.03.047</ArticleId>
            <ArticleId IdType="pubmed">24768310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalron A, Greenberg-Abrahami M, Gelav S, Achiron A. Effects of a new sensory re-education training tool on hand sensibility and manual dexterity in people with multiple sclerosis. NeuroRehabilitation. 2013;32(4):943–948. doi: 10.3233/NRE-130917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/NRE-130917</ArticleId>
            <ArticleId IdType="pubmed">23867419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamm CP, Mattle HP, Müri RM, Heldner MR, Blatter V, Bartlome S, et al.  Home-based training to improve manual dexterity in patients with multiple sclerosis: a randomized controlled trial. Mult Scler. 2015;21(12):1546–1556. doi: 10.1177/1352458514565959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514565959</ArticleId>
            <ArticleId IdType="pubmed">25623246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hervault M, Balto JM, Hubbard EA, Motl RW. Reliability, precision, and clinically important change of the Nine-Hole Peg Test in individuals with multiple sclerosis. Int J Rehabil Res. 2017;40(1):91–93. doi: 10.1097/MRR.0000000000000209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MRR.0000000000000209</ArticleId>
            <ArticleId IdType="pubmed">28059944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al.  Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262(8):1936–1945. doi: 10.1007/s00415-015-7797-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-7797-1</ArticleId>
            <ArticleId IdType="pubmed">26041616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7(2):97–113. doi: 10.1177/1756285613512712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756285613512712</ArticleId>
            <ArticleId IdType="pmc">PMC3932769</ArticleId>
            <ArticleId IdType="pubmed">24587826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35–40. doi: 10.1016/j.clineuro.2015.08.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2015.08.023</ArticleId>
            <ArticleId IdType="pubmed">26363365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Achiron A, Chapman J, Magalashvili D, et al.  Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS ONE. 2013;8(8):e71058. doi: 10.1371/journal.pone.0071058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0071058</ArticleId>
            <ArticleId IdType="pmc">PMC3731335</ArticleId>
            <ArticleId IdType="pubmed">23936485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olazarán J, Cruz I, Benito-León J, Morales JM, Duque P, Rivera-Navarro J. Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA Study. Eur Neurol. 2009;61(2):87–93. doi: 10.1159/000177940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000177940</ArticleId>
            <ArticleId IdType="pubmed">19039226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41(5):685–691. doi: 10.1212/wnl.41.5.685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.41.5.685</ArticleId>
            <ArticleId IdType="pubmed">2027484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amato MP, Krupp LB, Charvet LE, Penner I, Till C. Pediatric multiple sclerosis: cognition and mood. Neurology. 2016;87(9 Suppl 2):S82–S87. doi: 10.1212/WNL.0000000000002883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002883</ArticleId>
            <ArticleId IdType="pubmed">27572867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Julian L, Serafin D, Charvet L, Ackerson J, Benedict R, Braaten E, et al.  Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013;28(1):102–107. doi: 10.1177/0883073812464816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073812464816</ArticleId>
            <ArticleId IdType="pmc">PMC3652651</ArticleId>
            <ArticleId IdType="pubmed">23155206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33(3):219–227. doi: 10.1007/s10865-010-9247-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10865-010-9247-y</ArticleId>
            <ArticleId IdType="pubmed">20127401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol. 1996;53(2):185–188. doi: 10.1001/archneur.1996.00550020101021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1996.00550020101021</ArticleId>
            <ArticleId IdType="pubmed">8639070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrow SA, Rosehart H, Johnson AM. The effect of fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord. 2017;11:4–9. doi: 10.1016/j.msard.2016.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2016.10.011</ArticleId>
            <ArticleId IdType="pubmed">28104253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler. 2011;17(9):1141–1145. doi: 10.1177/1352458511404585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458511404585</ArticleId>
            <ArticleId IdType="pubmed">21561956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrow SA, Kaushik T, Zarevics P, Erlanger D, Bear MF, Munschauer FE, et al.  The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(7):1095–1102. doi: 10.1007/s00415-009-5074-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5074-x</ArticleId>
            <ArticleId IdType="pubmed">19263186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrow SA, Smerbeck A, Patrick K, Cookfair D, Weinstock-Guttman B, Benedict RH. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. J Neurol. 2013;260(2):489–497. doi: 10.1007/s00415-012-6663-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-012-6663-7</ArticleId>
            <ArticleId IdType="pubmed">23001556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, et al.  Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study. J Neurol Sci. 2016;363:69–76. doi: 10.1016/j.jns.2016.02.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2016.02.012</ArticleId>
            <ArticleId IdType="pubmed">27000224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huolman S, Hämäläinen P, Vorobyev V, Ruutiainen J, Parkkola R, Laine T, et al.  The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler. 2011;17(11):1351–1361. doi: 10.1177/1352458511412061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458511412061</ArticleId>
            <ArticleId IdType="pubmed">21846692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63(9):1579–1585. doi: 10.1212/01.wnl.0000142989.09633.5a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000142989.09633.5a</ArticleId>
            <ArticleId IdType="pubmed">15534239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jara M, Aquilina T, Aupperle P, Rabinowicz AL. Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug Healthc Patient Saf. 2015;7:169–174. doi: 10.2147/DHPS.S97113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DHPS.S97113</ArticleId>
            <ArticleId IdType="pmc">PMC4687626</ArticleId>
            <ArticleId IdType="pubmed">26719727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2019. Cited 19 Dec 2019. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/22250s017lbl.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Pikoulas TE, Fuller MA. Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012;46(7–8):1010–1015. doi: 10.1345/aph.1Q714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1345/aph.1Q714</ArticleId>
            <ArticleId IdType="pubmed">22764324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al.  Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018;90(6):278–288. doi: 10.1212/WNL.0000000000004977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004977</ArticleId>
            <ArticleId IdType="pmc">PMC5818015</ArticleId>
            <ArticleId IdType="pubmed">29343470</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
